Biohaven Pharmaceutical Holding Company Ltd.
BHVN
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute aā¦ read more
Healthcare
Biotechnology
1 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$16.66
Price+8.89%
$1.36
1Y
Price
Market Cap
$1.762b
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$3.836m
-
1y CAGR-33.3%
3y CAGR-25.0%
5y CAGREarnings
-$766.971m
-26.7%
1y CAGR-55.0%
3y CAGR-61.3%
5y CAGREPS
-$7.66
-19.2%
1y CAGR-25.9%
3y CAGR-39.5%
5y CAGRBook Value
$134.587m
$550.415m
Assets$415.828m
Liabilities$286.867m
DebtDebt to Assets
52.1%
-0.1x
Debt to EBITDAFree Cash Flow
-$646.432m
-7.4%
1y CAGR-45.7%
3y CAGR-55.9%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company